Podcasts about Retinal

Inherited retinal diseases can profoundly affect a child's vision and development, yet there are no approved drug treatments for most of these conditions in children. In this episode of Eye on Innovation, host Carey Powers speaks with Carmen Carrichio, CEO and founder of Raresight, about why pediatric inherited retinal diseases have historically received less attention and investment than adult diseases — and how advances in genetic testing and clinical assessment are beginning to change that.In this episode, learn about: Why treatments developed for adults cannot simply be applied to childrenWhere gene therapy may fit into the future of careRaresight's approach to developing treatments designed to remain in the eye longerHow these treatments will change the trajectory of a child's life RESOURCES: Carey Powers: Carey Powers, MBA | Ophthalmology Innovation Source  

Drs. Garg and Mehta discuss how advances in vitrectomy technology, imaging, and heads-up display systems are changing surgical decision-making and improving outcomes for diabetic retinopathy, tractional retinal detachments, and visually significant floaters. They emphasize earlier surgical intervention in select diabetic cases, careful patient selection and counseling, and the importance of ergonomics and visualization tools for both surgeon longevity and teaching.

In this episode, we review the current status of gene therapy for inherited retinal degenerations with Dr. Ninel Gregori, Professor of Clinical Ophthalmology, Bascom Palmer Eye Institute

Dr. Brian Ballios from the University of Toronto and Toronto Western Hospital returns to The Retina Channel for a comprehensive update on inherited retinal diseases (IRDs). We discuss the evolving landscape of gene therapy, including long-term experience with RPE65 therapy and emerging treatments for IRDs including antisense oligonucleotides, optogenetics, new therapies for Stargardt disease, stem cell and photoreceptor replacement strategies, and the importance of natural history studies in designing future clinical trials. Brian was the second-ever guest on The Retina Channel back in 2017, making his return for Episode 98 nearly nine years later a particularly special one. A fascinating discussion about how far the field has come — and where IRD treatment may be heading next.

Send us Fan MailThis week on Just MS News, we're focusing on two important areas of multiple sclerosis research: understanding progression and repairing damage.

In Europe, Science Corporation has commercially launched PRIMA, a retinal implant designed to restore central vision in people with geographic atrophy (GA). The treatment has been shown in clinical trials to restore functional central vision in people with GA who until now had no way to get lost central vision back. While PRIMA is available in Europe, it is still going through FDA approvals in the U.S. Geographic atrophy is an advanced form of age-related macular degeneration (AMD) that leads to progressive vision loss. AMD is the most common cause of blindness in individuals over the age of 55 in developed countries.

Ahead of her Gisbert Richard Lecture at the Euretina Congress in Vienna, Prof. Noemi Lois tells Prof. Nicole Eter why diabetic tractional retinal detachment is far more than a mechanical problem — and why we may be catching patients too late. They discuss the scarce evidence on risk factors, anti-VEGF before vitrectomy, tamponade choices, and what the EMERALD study means for clinic capacity

Retinal Implant- August 21st, 8PM Eastern (ACB Media 1) and repeats throughout the next seven days  The San Francisco Chronicle reports that a Stanford University scientist and ophthalmologist has invented a prosthetic retinal implant. The implant is the first to improve vision in older adults with a common form of blindness. The implant's inventor is Dr. Daniel Palanker. And Dr. Palanker will join us to talk about the device.  For more info related to this week's show, go to:  https://www.sfgate.com/bayarea/article/patients-get-vision-stanford-tech-21116556.php Ways to Connect to Speaking Out for the Blind  Amazon Alexa enabled device (RECOMMENDED) “Alexa, Ask ACB Media to play Media 1”. (1 = stream number). PC / browser access (RECOMMENDED):  Visit acbmedia.org at http://www.acbmedia.org/1 (1 = stream number). The site has a built-in media player and there is no need to install or use a media player on your device. Hit the play button and the stream will begin playing immediately. Smart device Access (RECOMMENDED):  Download “ACB Link” from your app store. Find “Radio” along the bottom of the screen, then “Menu” in the top left corner. Select “Live Streams” and then choose “ACB Media 1 - Mainstream.” Double tap the play button. Victor Reader Stream Access: Navigate to “Internet radio library” in the “online bookshelf”. Locate the Humanware playlist. From the playlist, select ACB Media 1 (1 = stream number) and hit play. Alternate Dial-In access  Dial 1 (518) 906-1820. Listen to the menu prompts and press 1.  IMPORTANT NOTE The ACB Radio Tuner is no longer supported. If you used the tuner in the past, you may access all ACB Media streams from acbmedia.org (see above) If you are using alternate ways to access ACB Media streams than those above (such as Tune In or Winamp using acbradio.org URL's, we kindly ask that you use one of the methods above.   Facebook page is at Speaking Out for the Blind and X (formerly Twitter) page is at SpeakOutfortheBlind (you may also access this at SpeakOutBlind).  Speaking Out show archive page is at https://speaking-out-for-the-blind.pinecast.co/

Interview with Rupesh Agrawal, MMed, MD, and James T. Rosenbaum, MD, authors of Standardization of Retinal Vasculitis Terminology With Consensus Definitions From a Delphi Panel. Hosted by Neil Bressler, MD. Related Content: Standardization of Retinal Vasculitis Terminology With Consensus Definitions From a Delphi Panel

Interview with Rupesh Agrawal, MMed, MD, and James T. Rosenbaum, MD, authors of Standardization of Retinal Vasculitis Terminology With Consensus Definitions From a Delphi Panel. Hosted by Neil Bressler, MD. Related Content: Standardization of Retinal Vasculitis Terminology With Consensus Definitions From a Delphi Panel

In most mammalian retinas, rods outnumber cones. But that ratio is flipped in ground squirrels, a quirk that helps Seth Blackshaw explore how retinal cells develop their identities.

Drs. Garg and Mehta focus on challenges and solutions in providing retinal care for patients—especially those with diabetes—including barriers like socioeconomic factors, transportation, insurance, and the need for coordinated, team-based care with other medical specialists. They highlight initiatives such as diabetic eye screening days and emerging technologies like tele-ophthalmology, home OCT, and AI-driven screening and monitoring to improve access, continuity of care, and visual outcomes.

Are you up to date on developments in technology for treating retinovascular disease? Credit available for this activity expires: 7/24/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/beyond-intervals-next-era-continuous-delivery-retinal-2026a1000mm4?ecd=bdc_podcast_libsyn_mscpedu

How did a home-based reseller become a global e-commerce leader for a 9-figure K-beauty brand? Discover her Amazon strategy, future-customer targeting, TikTok tactics, and smart AI tools.   ► Watch The Podcasts On YouTube: https://www.youtube.com/@Helium10SeriousSellersPodcast?sub_confirmation=1 ► Instagram: instagram.com/serioussellerspodcast ► Free Amazon Seller Chrome Extension: https://h10.me/extension ► Sign Up For Helium 10: https://h10.me/signup  (Use SSP10 To Save 10% For Life) ► Learn How To Sell on Amazon: https://h10.me/ft   Bradley Sutton takes the Serious Sellers Podcast on the road, and onto a moving rail bike in South Korea, for a conversation with Jenna, Global E-commerce Team Manager at TONYMOLY. Jenna shares how she went from studying law and working as a programmer to spending ten years raising her daughter, discovering e-commerce from home, and eventually building a successful international selling career. She began by reselling Korean sporting goods to US customers through eBay before shifting her attention to Amazon, where one business reached as much as $10,000 in monthly profit. Her success during the pandemic earned her recognition from Amazon Korea and opened the door to managing accounts for other companies. Jenna has now used Helium 10 for approximately five years, and her favorite tool is the Xray Chrome Extension. She uses Xray while browsing Amazon to quickly review estimated sales, keywords, and Best Sellers Rank, helping her evaluate products and marketplace opportunities without leaving the search results. Today, she applies that experience at TONYMOLY, a 20-year-old K-beauty company generating approximately $163 million in annual sales. Jenna also reveals an unusual long-term marketing strategy: targeting customers before they become the brand's core buyers. If current anti-aging customers are between 40 and 50, her team may create content for women closer to 35, building awareness years before the need becomes urgent. TONYMOLY and its newer brand, BONCEPT, also use TikTok and Meta to drive product discovery, while positioning Amazon as the more attractive place to complete the purchase. The company supports these strategies through close collaboration between its e-commerce, sales, and R&D teams, allowing it to respond quickly to fast-moving beauty trends. From emerging ingredients such as PDRN, retinol, and retinal to the use of AI for copywriting, images, videos, and English-language content, this episode offers a fascinating look at how a global beauty company combines marketplace data, creative storytelling, and product innovation. Jenna's journey proves that starting small does not limit where e-commerce can take you. By continuing to learn, adapting when marketplaces change, and understanding customers before competitors do, sellers can turn an unexpected opportunity into a truly global career. In episode 757 of the Serious Sellers Podcast, Bradley and Jenna discuss: 00:00 - Introduction 01:28 - Meet Jenna From TONYMOLY 02:38 - From Law And Programming To E-Commerce 03:34 - Starting A Home-Based eBay Business 05:55 - Moving From eBay To Amazon 07:52 - Reaching $10,000 In Monthly Profit 09:59 - Winning An Amazon Korea Competition 10:38 - Five Years Using Helium 10 10:46 - Why Xray Is Her Favorite Tool 11:28 - Managing Global E-Commerce For TONYMOLY 14:17 - Launching The New BONCEPT Brand 16:11 - Expanding K-Beauty Across Amazon Europe 17:58 - Targeting Customers Five Years Early 20:17 - Using TikTok To Drive Amazon Sales 22:00 - How R&D And E-Commerce Work Together 23:52 - Retinol, Retinal, And PDRN Trends 27:27 - Using AI For Global Content Creation

Johannes Galatsanos occupies an unusual dual perch in the quantum ecosystem. As a co-author of the inaugural MIT Quantum Index Report, he's helped map the entire quantum landscape at altitude; as co-founder and CEO of Diffraqtion, he's staked his career on one of its most under-discussed corners: quantum imaging. The company spun out of Saikat Guha's lab at the University of Maryland after more than a decade of DARPA-funded research, emerged from stealth in January 2026 with $4.2M in pre-seed funding, and is now racing toward on-sky telescope demonstrations and a 2028 satellite launch.This episode is for listeners who want a technically honest look at where the "quantum" label is doing real work in a sensor versus where it's shading into sophisticated photonics and analog computing. If you care about how quantum technologies actually reach the world — through markets, contracts, and hardware that ships — this conversation gives you a specific, concrete example to think with.What You'll LearnWhy a conventional camera can lose roughly 95% of the information a photon carries, and what quantum Fisher information theory says about recovering itHow Diffraqtion's device processes light directly in the photonic domain before converting it to electronic information — and why that matters for shot noiseThe honest answer to "is this really quantum?" — including where the technology sits between quantum information theory, photonics, and analog computingWhy a 6U CubeSat with a 10-centimeter aperture can plausibly compete with school-bus-sized observation satellites for specific tasksHow a "diffractive neural network" runs image classification at the speed of light with negligible power consumptionThe difference between Diffraqtion's hard-coded Gen 1 camera and the reprogrammable Gen 2 that can swap algorithms in orbit (canopy detection over the Amazon, ship detection over the Atlantic)Why the Habitable Worlds Observatory needs a coronagraph capability — and how you can build one by processing light rather than blocking itWhat quantum sensing needs from policy, capital, and PR to escape the shadow of quantum computingResources & LinksGuest & CompanyDiffraqtion — Company homepage; describes the technology, NASA/DARPA lineage, and the "quantum eye" framing referenced in the conversation.Johannes Galatsanos on LinkedIn — Recent activity including SmallSat Europe, the NASA Space to Soil Challenge, and GQIG Summit talks on quantum imaging.Papers & ReportsQuantum Index Report 2025 (arXiv) — The preprint of the MIT QIR, co-authored by Galatsanos. Essential reading for anyone trying to see the quantum landscape as a whole.MIT Sloan — New MIT Report Captures State of Quantum Computing — Background on the QIR and Galatsanos's research role at the MIT Initiative on the Digital Economy.MIT Sloan — Quantum Report Charts Growing Business Interest — Further QIR findings on the growth in corporate quantum mentions.Press & CoverageDiffraqtion Pre-Seed Announcement (PR Newswire) — Official release covering the $4.2M raise, DARPA contract, and founding team.Breaking Defense — DARPA Backs Diffraqtion — The most in-depth interview on the DARPA SBIR contract and programmable light plates.The Quantum Insider — Diffraqtion $4.2M Raise — Investor context including quotes from Chad Rigetti; technical claims on resolution and processing.Payload Space — Diffraqtion Emerges from Stealth — Commercial framing around the 6U CubeSat cost model.Defense One — Quantum Cameras Could Remake Space-Based Intelligence — Policy and defense framing.SponsorCisco Universal Quantum Switch — Outshift by Cisco — Cisco's incubation engine, building a scalable quantum network on open standards and vendor-agnostic architecture.Key Quotes & InsightsOn quantum information loss: "When you do a direct image… you lose something like 95% of information from that photon. So you leave 95% on the table, and the question was: how do you extract that back?"On what "quantum" really means here: Galatsanos is refreshingly candid — the device uses quantum Fisher information theory to set the physical limit and configure the hardware, but the runtime processing is closer to analog photonic computing than to gate-based quantum computing. He describes it as sitting between "quantum 1.0" and quantum sensing.On the frog's-eye analogy: Retinal ganglion cells can process shapes and trajectories faster than the brain — which is why you can catch a baseball or a falling fork before you consciously see it. Diffraqtion is trying to give satellites and robots the same kind of reflex.On the JPEG as a historical artifact: "JPEG was a little bit of a logical step… but now the thought is, forget about it — you don't even need that. The light itself already will tell you." The machine, unlike a human operator, doesn't need an image.On why quantum sensing lags in the discourse: Insight — quantum computing benefits from a single unifying narrative that every vendor can pull on. Quantum sensing has to invent its own story from scratch for each modality, which is a structural PR disadvantage more than a technical one.Related EpisodesEp. 65 — Quantum sensitivity breakthrough with Eli Levenson-Falk — On protocols that push measurements beyond conventional limits; a natural companion to the Fisher information discussion.Ep. 16 — Operating at the Quantum Limit with Dr. Dana Anderson — Infleqtion's CSO on quantum sensing alongside computing; useful context for why sensing is closer to deployment.Ep. 68 — Incubating quantum innovation with Vijoy Pandey of Outshift by Cisco — On quantum networks solving real problems today; a parallel to Diffraqtion's near-term deployment argument.Ep. 63 — A Programming Language for Quantum Simulations with Xiaodi Wu — Also from the University of...

Drs. Kat Talcott and Akshay Thomas join for a journal club podcast discussion:‍‍Mark Cuban Cost Plus Ophthalmology Medications (https://www.aaojournal.org/article/S0161-6420(26)00378-7/fulltext)Resident Continuity Clinics (https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2848897)PDR Long-Term Outcomes (https://www.ophthalmologyretina.org/article/S2468-6530(26)00218-6/abstract)Marginal Outer Retinal Ridge in PDR (https://www.ophthalmologyretina.org/article/S2468-6530(26)00274-5/abstract)‍ ‍

Drs. Safa Rahmani and Kat Talcott join to preview the July 2026 of Retinal Physician found online at http://www.retinalphysician.com. Topics covered include intraocular tamponades and elevation impact on surgical decision making.

What if one of the earliest clues to Alzheimer's disease could be found during a routine eye exam? In this episode of Tomorrow's Cure, host Lindsey Seavert sits down with Dr. Oana Dumitrascu, a neurologist at Mayo Clinic, and Dr. Yalin Wang, a researcher at Arizona State University, to explore how retinal imaging and artificial intelligence may help identify signs of Alzheimer's disease years before symptoms appear. Together, they discuss the science behind “seeing the brain through the eye,” how AI can detect patterns invisible to the human eye, and why earlier detection could transform research, prevention, and patient care. This conversation highlights an exciting intersection of neuroscience, artificial intelligence, and preventive medicine. How to listen and stay connected: Subscribe to Tomorrow's Cure on your favorite podcast app and follow the show so you never miss an episode. Get the latest health information from Mayo Clinic's experts—subscribe to Mayo Clinic's newsletter for free today: https://mayocl.in/3EcNPNc Connect with Mayo Clinic: Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/ Follow Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/ Follow Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinic Follow Mayo Clinic on Threads: https://www.threads.net/@mayoclinic

Does retinal capillary non-perfusion reliably predict functional vision loss in DR? And does the answer change how retina specialists treat it? In this episode of New Retina Radio Journal Club with VBS, Barton Blackorby, MD; Katherine Talcott, MD; and Hong-Uyen Hua, MD, discuss a prospective longitudinal cohort study examining the association between retinal sensitivity and perfusion over 2 years in patients with DR.

Drs. Yiu and Emami wrap-up their discussion of the 49th Annual Macula Society Meeting, focusing on new and emerging treatments for retinal diseases—such as gene therapies and longer‑acting eye injections—and reflect on both their promise and current limitations. They note that while these advances, along with tools like AI and multi-omics, are exciting, they are only beginning to influence everyday clinical practice and patient counseling.

Your eyes reveal what you cannot see. Advanced OCT and OCT Angiography technology now allows eye care professionals to detect and prevent diseases that would otherwise lead to blindness and to diagnose systemic conditions like diabetes, hypertension, and cardiovascular disease before symptoms appear. In this episode, Dr. Kerry Gelb sits down with Dr. Carolyn Majcher, a leading expert in retinal imaging and vitreoretinal disease, to explore how this breakthrough technology is transforming preventive medicine. ❤️ WHY THIS MATTERS: Early detection saves vision. Early detection saves lives. Eye imaging now detects: ✓ Diabetes (before the patient knows) ✓ Hypertension (silently damaging organs) ✓ Cardiovascular disease (showing warning signs in the retina) ✓ Retinal diseases (before blindness occurs) ✓ Systemic conditions (through the eye as a biomarker) Connect with Dr. Carolyn Majcher: https://www.instagram.com/retina_queen/

Professor of ophthalmology Daniel Palanker is a physicist who has combined his skills in optics and electronics to create PRIMA – the Photovoltaic Retinal Implant. Inserted beneath the retina, it restores vision to patients blinded by retinal degeneration, allowing them to read and write – and with the next-generation software, to recognize faces. PRIMA's photovoltaic pixels act like tiny solar panels, converting light into electricity to stimulate the remaining retinal neurons. Better yet, the growing field of brain-computer interfaces may have implications beyond ophthalmology. “Unlike medicine, where the road ends with curing a disease or restoring lost function, the prospects for brain-machine interfaces may be infinite,” Palanker tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Daniel Palanker Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Daniel Palanker, a professor of ophthalmology and electrical engineering at Stanford University. (00:03:17) Path into Ophthalmology How Palanker's background in physics and optics led him to vision research. (00:04:33) How Vision Works A primer on the eye, retina, photoreceptors, and the neural code of sight. (00:08:50) Retinal Degeneration How diseases like macular degeneration and inherited retinal disorders damage vision. (00:13:18) The PRIMA Implant How a photovoltaic retinal implant converts light into electrical stimulation. (00:15:05) Augmented Reality Glasses How camera-equipped glasses amplify and project images to power the implant. (00:17:42) From Reading to Face Recognition Why grayscale vision is the next step toward recognizing faces. (00:20:18) Implanting the Device How the wireless chip is placed under the retina and powered by light. (00:21:45) Replaceable Vision Technology How future generations of implants could be swapped in for higher resolution. (00:22:28) Limits of Resolution Why geometry and proximity to neurons determine how small pixels can get. (00:24:00) Moving to 3D Electrodes How pillar-shaped electrodes help neurons move closer to the implant. (00:26:28) Clinical Path Forward The status of European trials, FDA discussions, and future patient access. (00:28:10) Safety and Real-World Use What trials reveal about surgical risks, durability, and patients using implants at home. (00:30:11) Future In a Minute Rapid-fire Q&A: neural coding, brain-machine interfaces, and restoring vision. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Do the benefits really outweigh the risks when it comes to the use of thrombolytic drugs for central retinal artery occlusion (CRAO)? Drs. Amanda Henderson and Michael Carper weigh in on the recently published Tenecteplase in Central Retinal Artery Occlusion Study (TenCRAOS) and how ophthalmologists should proceed in their management of CRAO with tenecteplase (TNK) or another tissue plasminogen activator (tPA). For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.

Dr. Casandra MacLeod discusses central retinal artery occlusions, recent trials, and those anticipated in the future.  Show citation:  Préterre C, Gaultier A, Obadia M, et al. Intravenous alteplase versus oral aspirin for acute central retinal artery occlusion within 4·5 h of severe vision loss (THEIA): a multicentre, double-dummy, patient-blinded and assessor-blinded, randomised, controlled, phase 3 trial. Lancet Neurol. 2025;24(11):909-919. doi:10.1016/S1474-4422(25)00308-4  Poli S, Grohmann C, Wenzel DA, et al. Early REperfusion therapy with intravenous alteplase for recovery of VISION in acute central retinal artery occlusion (REVISION): Study protocol of a phase III trial. Int J Stroke. 2024;19(7):823-829. doi:10.1177/17474930241248516  Ryan SJ, Jørstad ØK, Skjelland M, et al. A Randomized Trial of Tenecteplase in Acute Central Retinal Artery Occlusion. N Engl J Med. 2026;394(5):442-450. doi:10.1056/NEJMoa2508515 Show transcript:  Dr. Casandra MacLeod Hello, this is Casandra MacLeod, a neurology resident at Cleveland Clinic with today's Neurology Minute. Today we will be discussing central retinal artery occlusions, or CRAOs, and the recent trials that have come out and even those further on the horizon. The 2026 American Heart Association and American Stroke Association guidelines for the early management of patients with acute ischemic stroke were recently published and in them highlight the uncertainty around the treatment of acute CRAOs with intravenous thrombolysis, even when the patient presents within four and a half hours and is otherwise eligible. These guidelines come after two recent trials, which we will further discuss. The thrombolysis in patients with acute central retinal artery occlusion, or the THEIA trial, was published in the November issue of Lancet Neurology. This multicenter trial out of France randomized 70 patients with acute CRAOs presented within four and a half hours of time from last known well to either receive IV alteplase and oral placebo or IV placebo and oral aspirin. While safety measures showed no symptomatic hemorrhage event, although they did have one asymptomatic intracerebral hemorrhage occur, the primary outcomes, which included visual acuity improvement at one month, showed some evidence for a trend of improved acuity in the IV thrombolytic group at 66% compared to 48 in the aspirin group, it did not reach significant. And now more recently, the Tenecteplase in central retinal artery occlusion study, or TenCRAOs, was published in the January 2026 issue of The New England Journal of Medicine. TenCRAOs was a six European country multicenter trial that randomized 78 patients with CRAOs all presenting within four and a half hours of time from last known well to either receive IV Tenecteplase or aspirin, both with placebo-matching as in THEIA. The primary outcomes of TenCRAOs also included visual acuity at one month, but unfortunately this trial also did not show [inaudible 00:02:07]. They showed 20% in the IV TNK group compared to 24% in aspirin. And additionally, there was one fatal intracerebral hemorrhage in the TNK group that should be considered. Overall, the AHA and ASA guidelines state the usefulness of treatment with intravenous thrombolysis is uncertain. And this is based largely on these studies as neither trial showed improved visual recovery. Although both of these trials are underpowered, leading many to believe that the jury is still out on the use of IV thrombolytics in CRAOs. But importantly, stay on the lookout for one last trial. The early reperfusion therapy with intravenous alteplase for recovery of vision and acute central retinal artery occlusion, or the Revision trial, is actively recruiting. Revision is similar in design as THEIA, but with a goal of up to 422 total patients for a goal of a well-powered study to guide decision making. 

Today's episode is a very special one. We are joined by Anna and her mother, Chelle, to discuss what it is like to live with Leber congenital amaurosis (or LCA) and to understand the patient experience of receiving retinal gene therapy with Luxturna, the first FDA approved gene therapy in medicine.  Subscribe to the podcast:  https://MayoClinicOphthalmology.podbean.com   Follow and reach out to us on X and IG: @mayocliniceye 

Drs. Yiu and Emami continue their wrap-up of the highlights from the 49th Annual Macula Society Meeting, focusing on new developments in imaging technologies, AI, and drug delivery for retinal diseases. They also touch on emerging basic science topics like the gut microbiome and metabolomics, and how these may support more personalized, systems-level approaches to eye disease.

Too busy to read the Lens? Listen to our weekly summary here! In this week's episode we discuss…High-dose Aflibercept holds strong at 2 years for central diabetic macular edema with significantly fewer injections.Retinal disease burden in the United States is vast and unevenly distributed.Retinal imaging may serve as a noninvasive window into microvascular kidney disease.Keratoconus may be underrecognized in older adults.

In our latest episode, we discuss the use of inhibitors of IL-6 in the treatment of retinal disease with Dr. Steven M. Yeh, Stanley M. Truhlsen, Jr. , Chair of Ophthalmology a the University of Nebraska.

In this episode, we discuss the use of aflibercept 8mg for the management of retinal vein occlusion and the results of the QUASAR study with Dr. Sunir Garg, Co Director of Retina Research at the Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/COPE information, and to apply for credit, please visit us at PeerView.com/PVU865. CME/COPE credit will be available until April 26, 2027.Reimagining Retinal Treatment: The Promise of Novel Delivery Mechanisms for Anti-VEGF Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Genentech, a member of the Roche Group.Disclosure information is available at the beginning of the video presentation.

Drs. Mohsin Ali and Akshay Thomas join to preview the May 2026 edition of Retinal Physician found online at http://www.retinalphysician.com. Discussion includes management options for diabetic retinopathy and diabetic macular edema, artificial intelligence screening for diabetic retinopathy, and the PRIMA subretinal implant.

On today’s episode of Spendy Savey, Kelly and Leigh are sharing their latest beauty obsessions, including the $3.70 Korean beauty find that targets dark circles, the "motor oil" eyeliner Leigh is surprisingly obsessed with and the cult-status hair scrub Kelly wishes she could experience for the first time all over again. Plus, Leigh explains why she’s carrying around what looks like a "dirty towel" from Amazon, and we unbox a brand-new clinical hair range that claims our scalps are aging faster than our faces... (Rude!) EVERYTHING MENTIONED: SPENDY: KELLY: Anastasia Beverly Hills Magic Touch Blush Trio in Peach, $70. LEIGH: ESK Ultimate Gold A Night Cream, $115. SAVEY: KELLY: Mary & May Tranexamic Acid + Glutathione Eye Cream, $23. LEIGH: Mecca Max Zoom Zip Liner in Motor Oil, $22. NEWBIE: KELLY: Chloé Atelier des Fleurs "The Mediterranean Essences" Collection, from $60. LEIGH: Nioxin Pro Clinical Age Defense Range, from $57. SMS/EMPTY KELLY: Christophe Robin Cleansing Purifying Scrub with Sea Salt, $72. LEIGH: Self-Adhesive Magic Cloth Makeup Bag, $22. WHAT'S ON KELLY'S FACE: Go-To Very Glowy Primer, $48. Natasha Denona HY-Glam Foundation (N3), $94. Anastasia Beverly Hills Magic Touch Blush Trio in Peach, $70. Rare Beauty Warm Wishes Soft Matte Powder Bronzer in Sun Blaze, $51. Holme Beauty Soft Set Eye Primer in Blanche, $35. Sephora Collection 12H Intense Ink Classic Line Felt Eyeliner in Espresso, $24. Benefit Precisely My Brow in 3.5, $49. W7 Tube It Mascara, $6.99. Makeup By Mario Surrealskin™ Soft Setting Spray, $72. Laneige Juicepop Box Lip Tint in 06 Classic Red, $ 30. DON'T FORGET: Win a $2,000 Bed Threads voucher. Subscribe to Mamamia here before April 30 to be automatically entered. Current subscriber? You're already in the draw. T&Cs apply. Watch & Subscribe on YouTube, this episode drops tonight at 7pm! Catch it here. Follow us on Instagram: @youbeautypodcast Follow us on TikTok: @youbeautypod Join our You Beauty Facebook Group here GET IN TOUCH: Got a beauty question you want answered? Email us at youbeauty@mamamia.com.au or send us a voice note on Instagram! You Beauty is a podcast by Mamamia. Listen to more Mamamia podcasts here. For our product recommendations, exclusive beauty news, reviews, articles, deals and much more - sign up for our free You Beauty weekly newsletter here Subscribe to Mamamia here CREDITS: Hosts: Kelly McCarren & Leigh Campbell Producer: Zara Sengstock & Ella Maitland Audio Producer: Tegan Sadler Video Producer: Artemi Kokkaris Just so you know - some of the links in these notes are affiliate links, which means we might earn a small commission if you buy through them. It doesn’t cost you anything extra, and it helps support the show. Happy shopping! Mamamia acknowledges the traditional owners of the land on which we have recorded this podcast.Become a Mamamia subscriber: https://www.mamamia.com.au/subscribeSee omnystudio.com/listener for privacy information.

Dr. Mitul Mehta joins to share career perspectives in retina and wearable technology for retinal disease, including his company Eyedaptic.Dr. Mehta does have a financial disclosure for Eyedaptic.

Broadcast from KSQD, Santa Cruz on 4-09-2026: Dr. Dawn shares a follow-up from an emailer in Switzerland providing seven functional medicine practitioner addresses near Zurich and Aargau, noting that Switzerland uses different terminology but is actually an "epicenter of functional medicine." Dr. Dawn calls for support of the bipartisan Break Up Big Medicine Act, modeled on Glass-Steagall, which would prohibit common ownership of medical providers with insurers, pharmacy benefit managers, or drug wholesalers. She explains how vertical integration by companies like UnitedHealth, CVS/Aetna, and Cigna allows them to game medical loss ratio requirements through self-dealing while driving up costs. A European clinical trial implanted 2mm x 2mm light sensors beneath the retinas of 38 people with advanced macular degeneration, with 80% gaining clinically meaningful improvement (two lines on the vision chart) after one year. The device bypasses damaged rods and cones, sending camera images from glasses directly to the optic nerve. Dr. Dawn explains that air temperature warnings are measured in shade, but direct sunlight can add 20°C to heat exposure. Heat stroke triggers gut permeability, releasing lipopolysaccharides that cause cytokine storms and organ failure. She advises fans over air conditioning when possible, shade, hydration, and loose natural-fabric clothing. An emailer asks if low-dose oral strontium supplementation has the same problem as pharmaceutical strontium. Dr. Dawn confirms it improves bone density scores without reducing fracture risk, and recommends telopeptide testing to monitor actual bone loss after discontinuing. An emailer's doctor wants to prescribe high-dose dexamethasone for low platelets. Dr. Dawn advises against rushing to steroids since platelets of 40 are adequate for clotting, recommending a hematology consultation and repeat testing with citrated blood. Dr. Dawn reviews fiber types: wheat dextrin (Benefiber) is fermentable but technically gluten-free; guar fiber (Sunfiber) ferments slowly and works for low-FODMAP diets; inulin feeds bifidobacteria and produces anti-inflammatory short-chain fatty acids; methylcellulose (Citrucel) is non-fermentable; and psyllium (Metamucil) is facing a class action lawsuit over undisclosed lead contamination. An emailer with varicose veins reports recurring superficial blood clots. Dr. Dawn explains these don't travel to lungs like deep vein clots, but repeated clotting suggests possible thrombophilia requiring workup. She recommends consulting a vascular surgeon about superficial venous ligation under local anesthesia. Analysis of 25,000 wearable users found that three daily "exercise snacks" of just 1-2 minutes of vigorous activity (stairs, running for a bus) reduced all-cause mortality by 38-40%. Benefits plateau around 7,500 steps daily, and simply standing up every couple of hours dramatically reduces sedentary risks.

In this episode, we are diving deep into the retinal (retinaldehyde) landscape to see how current market offerings stack up. Following our technical breakdown of retinol versus retinal, we shift our focus to real-world testing of popular formulations from Krave Beauty, Prequel, Celimax, and Medik8. We examine the scientific validity of concentration ranges—from the entry-level 0.05% to the more intense 0.24%—and discuss how different textures and price points impact the user experience for various skin types. Whether you are a retinoid rookie or a seasoned pro, we provide the detailed assessment on the data to find the right one for your particular skinario.   Timestamps: 00:00 - Intro 02:18 - Product Aesthetics & Textures 08:35 - Krave Beauty 24 Retinal Decode 10:21 - Prequel Retinal Renewal Decode 15:48 - Celimax Vita-A Retinal Shot Decode 22:00 - Medik8 Crystal Retinal 6 Decode 23:51 - Is Retinal 11x faster than Retinol? 28:39 - Chemists' Favorite Retinal (Personal favorites and usage recommendations)   Products Mentioned: Shop everything mentioned in this video here: https://shopmy.us/collections/4698294 PREQUEL | Retinal Renew Retinaldehyde Gel: https://go.shopmy.us/p-51236222 CELIMAX | The Vita-A Retinal Shot Tightening Booster: https://go.shopmy.us/p-51236269 KRAVEBEAUTY | 24 Carrot Retinal Gentle 0 05 Retinal Serum: https://go.shopmy.us/p-51236391 MEDIK8 | Crystal Retinal 6 Serum: https://go.shopmy.us/p-51236422 (use code: CHEMISTCONFESSIONS for 15% off) Shop more of my favorite products here: https://shopmy.us/chemistconfessions    

Send us Fan MailIn this Journal Club episode, Ben and Daphna explore an exciting new frontier in neonatology: oculomics. Reviewing a recent paper from JAMA Ophthalmology, they discuss how deep learning models applied to routine ROP screening images can predict the development of BPD and pulmonary hypertension in preterm infants. By combining visual features extracted via neural networks with standard demographic data, researchers achieved impressive predictive accuracy weeks before clinical diagnosis is typically made. Tune in to hear how the eyes might just be the window to the neonatal pulmonary vasculature!----Deep Learning-Based Prediction of Cardiopulmonary Disease in Retinal Images of Premature Infants. Singh P, Kumar S, Tyagi R, Young BK, Jordan BK, Scottoline B, Evers PD, Ostmo S, Coyner AS, Lin WC, Gupta A, Erdogmus D, Chan RVP, McCourt EA, Barry JS, McEvoy CT, Chiang MF, Campbell JP, Kalpathy-Cramer J.JAMA Ophthalmol. 2026 Jan 22:e255814. doi: 10.1001/jamaophthalmol.2025.5814. Online ahead of print.PMID: 41569552Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

We are diving back into the "rumor mill" of the retinoid world! Is Retinal actually better than Retinol, or is it just better marketing? In this episode, we revisit the Retinol vs. Retinal debate with new 2026 data. We break down what the evidence says about the retinoid conversion pathway into retinoic acid. We look at the latest clinical evidence to help you decide if it's time to switch your anti-aging active or stay the course with your current skincare routine. Episode Timestamps 0:00 - Intro: Revisiting the Retinoid Rumor Mill 1:34 - Why Retinal (Retinaldehyde) is Growing in Popularity 2:01 - The Science of Retinoic Acid Conversion Steps 5:30 - What the Data Shows (Retinol vs. Retinal ex vivo Conversion) 9:15 - Retinal vs. Retinol: Potency & Efficacy Realities 14:40 - Is Retinal Actually Gentler? (Irritation & Skin Barrier) 18:20 - Debunking High-Concentration Retinoid Myths 23:55 - Reviewing Recent Retinal Product Launches 28:10 - How to Choose: Retinol or Retinal for your Skin Type? 36:22 - Final Verdict: Should You Switch Your Active? Resources & Mentions Retinal vs Retinol on the CC Blog: https://chemistconfessions.com/blogs/retinal-is-it-better-than-retinol Retinol vs Tretinoin: https://chemistconfessions.com/blogs/tretinoin-vs-retinol Follow us on IG : @chemist.confessions #chemistconfessions #retinal #retinol #skincarescience #antiaging #retinaldehyde #skincareroutine

Host: Darryl S. Chutka, M.D.  Guest: Brittni A. Scruggs, M.D., Ph.D.  There are a variety of eye disorders which involve the retina, and they all have the potential to cause significant vision loss or blindness if not detected early. Two of the most common retinal disorders we see in primary care include diabetic retinopathy and macular degeneration. Since most health conditions affecting the retina are asymptomatic early in their course making patient screening and risk factor management an important task for primary care clinicians. Appropriate referrals to an ophthalmologist can result in effective treatment and improved outcomes. Which patients are at risk of retinal disorders? What are some “red flag” symptoms which should give us concern? Which medications we prescribe can affect the retina? This podcast is about retinal disorders, and I'll be asking these questions and more of my guest, Dr. Brittni Scruggs, an ophthalmologist and retinal surgeon at the Mayo Clinic.  Connect with us! Mayo Clinic Talks Podcast Season 6 | Mayo Clinic School of Continuous Professional Development 

To have Dr. Morse answer a question, visit: https://drmorses.tv/ask/ All of Dr. Morse's and his son's websites under one roof: https://handcrafted.health/ Facebook Page: https://www.facebook.com/handcrafted.health 00:00:00 - Intro - New Class on the Spirituality of Naturopathy 00:04:05 - Chronic Fatigue - Balance Issues - Brain Fog 00:35:14 - Adenoidectomy - Tonsillectomy 00:45:27 - Retinal Detachment and Degeneration, Corneal Thinning/ Bloating - Low Thyroid 01:08:16 - Chronic Pain - Healing Journey  01:24:42 - Breast Tumor 00:04:05 - Chronic Fatigue - Balance Issues - Brain Fog For the last 7 years, I've had an on and off feeling, like I'm on a boat when walking. 00:35:14 - Adenoidectomy - Tonsillectomy I deeply regret this. Can they grow back? 00:45:27 - Retinal Detachment and Degeneration, Corneal Thinning/ Bloating - Low Thyroid Is it possible to regenerate retinas and the eyes structure, damaged through treatments? 01:08:16 - Chronic Pain - Healing Journey  I want to snack on fruit during the day, but the gas/bloat makes me embarrassed. 01:24:42 - Breast Tumor I started to have a kind of a cyst on the left breast, it's now up to 7-9 cm in diameter.

02-24-26 - Obama On Podcast Confirmed We've Seen Aliens - Holmberg Explains What Happened To Prompt His Retinal Surgery And Encourages People To Have Their Eyes CheckedSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.